Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24375911 | 0.74 | CYP1A2 (0.41) | NCF1 | |
| SCHEMBL6074025 | 0.73 | — | — | |
| SCHEMBL6073725 | 0.70 | NCF1 (0.39) | NCF1HCAR3 | |
| SCHEMBL6073576 | 0.67 | FGFR1 (0.38) | — | |
| SCHEMBL5407960 | 0.66 | CYP1A2 (0.30) | — | |
| SCHEMBL2734677 | 0.65 | MAPK8 (0.38) | — | |
| SCHEMBL5410513 | 0.65 | NPC1 (0.37) | — | |
| SCHEMBL5408100 | 0.62 | TDO2 (0.37) | — | |
| SCHEMBL28091589 | 0.62 | NCF1 (0.41) | NCF1HCAR3 | |
| SCHEMBL13233227 | 0.62 | FGFR1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| CN-1395578-A | Byrido [2,3-d] pyrimidine-2, 7-diamine kinase inhibitors | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | NCF1 1813/4885HCAR3 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.